Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3

Long QT Syndrome Type 3 Clinical Trial

Official title: A Phase 3, Single-Blind Study to Evaluate the Effect of Eleclazine (GS-6615) on Shortening of the QT Interval, Safety, and Tolerability in Subjects With Long QT Syndrome Type 3

Status Terminated

Clinical Trial Summary

The primary objective of this study is to evaluate the effect of oral eleclazine on mean daytime QTcF interval after 24 weeks of treatment with elecalzine in participants with long QT syndrome Type 3. During the single-blind treatment period (24 weeks), participants will receive eleclazine and/or eleclazine placebo. Following the single-blind treatment period, participants who have not permanently discontinued study drug will be eligible, at the discretion of the investigator, to continue receiving eleclazine during an open-label extension (OLE) phase.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Long QT Syndrome
• Long QT Syndrome Type 3
• Syndrome

• NCT number: NCT02300558
• Study type: Interventional
• Source: Gilead Sciences
• Status: Terminated
• Phase: Phase 3
• Start date: December 17, 2014
• Completion date: February 15, 2017